Certain studies indicate that elevated levels of CD68+ macrophages are linked to better patient outcomes when effectively treated with therapies like rituximab [21], while others point towards a poor prognosis associated with high TAM density in various lymphoma types [22]. The gene discussed is CD68; the disease is lymphoma.